Drug Trial Radar · NCT04988386
Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
Last checked: Nov 19, 2026Latest source record: Oct 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
389
Actual
Start
Oct 27, 2021
Primary completion
Apr 15, 2028
Study completion May 15, 2028
Sponsor
- Lead sponsor
- Eidos Therapeutics, a BridgeBio companyIndustry
- Sponsor type
- Industry
- First posted
- Aug 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)
Conditions
- Amyloid Cardiomyopathy, Transthyretin-Related
Interventions
Acoramidis (AG10)Drug
Acoramidis (AG10) twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent Adverse Events [Safety and Tolerability]Time frame: 60 months
Locations
72 sites in 17 countries. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center
Los Angeles, California
University of Colorado Hospital - Anschutz Medical Campus
Aurora, Colorado
Northwestern University
Chicago, Illinois
University of Chicago Medical Center
Chicago, Illinois
NorthShore University Health System
Evanston, Illinois
MedStar Medical Group Cardiology at Franklin Square
Baltimore, Maryland
Boston University Medical Center General Clinical Research Unit
Boston, Massachusetts
Mayo Clinic - Rochester
Rochester, Minnesota
Saint Luke's Hospital of Kansas City
Kansas City, Missouri
Washington University
St Louis, Missouri
New York University Langone Health
New York, New York
Columbia University Irving Medical Center
New York, New York
Laurelton Heart Specialists
Rosedale, New York
Montefiore Medical Center at Hutchinson
The Bronx, New York
Duke University Health System - Duke Clinic
Durham, North Carolina
Cleveland Clinic Main Campus
Cleveland, Ohio
Oregon Health & Science University
Portland, Oregon
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center (UPMC)
Pittsburgh, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
University of Texas Southwestern Medical Center
Dallas, Texas
University of Utah
Salt Lake City, Utah
Virginia Commonwealth University Health System
Richmond, Virginia
Roanoke Heart Institute
Roanoke, Virginia
University of Washington School of Medicine
Seattle, Washington
Providence Sacred Heart Children's Hospital
Spokane, Washington
Saint Vincent's Hospital Sydney
Darlinghurst, New South Wales, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Royal Hobart Hospital
Hobart, Tasmania, Australia
Box Hill Hospital
Box Hill, Victoria, Australia
Fiona Stanley Hospital
Murdoch, Western Australia, Australia
Ziekenhuis Oost-Limburg
Genk, Limburg, Belgium
Algemeen Ziekenhuis Sint-Jan Brugge-Oostende - Campus Sint-Jan
Bruges, West Vlaanderen, Belgium
Instituto de Cardiologia do Rio Grande do Sul
Porto Alegre, Rio Grande do Sul, Brazil
Centro Avançado de Pesquisa e Estudos para o Diagnóstico CAPED
Ribeirão Preto, São Paulo, Brazil
Instituto do Coração de São Paulo
São Paulo, São Paulo, Brazil
Vancouver General Hospital
Vancouver, British Columbia, Canada
Saint Boniface Hospital
Winnipeg, Manitoba, Canada
Queen Elizabeth II Health Sciences Centre - Halifax Infirmary
Halifax, Nova Scotia, Canada
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.